99mTcPSMA放射引导手术在寡复发前列腺癌中的随机对照TRACE-II试验
TRACE-II是一项前瞻性随机对照试验,拟纳入60例PSMA PET/CT显示≤2个淋巴结或盆腔局部寡复发的前列腺癌患者,1:1随机接受6个月ADT(A组)或6个月ADT联合PSMA放射引导手术(B组),主要终点为24个月临床无进展生存期。
要点
- PSMA放射引导手术联合短期ADT可能对寡复发前列腺癌患者具有肿瘤学获益。
- 主要终点为24个月临床无进展生存期,样本量60例(每组30例),把握度80%检测至少30%绝对差异。
- 次要终点包括2、5、10年无转移生存、2年生化无进展生存及患者报告生活质量。
核心结论
- PSMA放射引导手术联合短期ADT可能对寡复发前列腺癌患者具有肿瘤学获益,这是首个随机对照试验正在评估该联合治疗的潜在肿瘤学获益并关注维持生活质量。
研究设计与样本
- TRACE-II为研究者发起的前瞻性随机对照临床试验,计划纳入60例年龄>18岁、根治性前列腺切除或放疗后激素敏感性复发且PSMA PET/CT显示≤2个淋巴结或盆腔局部寡复发的患者,1:1随机分入6个月ADT组(A组)或6个月ADT联合放射引导手术组(B组)。
主要发现
- 主要目的为确定24个月临床无进展生存期,放射引导手术后临床无进展生存期定义为治疗开始至PSMA-PET/CT提示或症状相关的再复发(任何N1或M1)或任何原因死亡的时间。
- 次要目的包括2、5和10年无转移生存、2年生化无进展生存及2、5和10年患者报告生活质量。
- 计划每组30例,把握度80%检测两组随机化后2年临床无进展生存期至少30%的绝对差异,预计3年入组完成,研究总时长5年。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate whether combination treatment of prostate-specific membrane antigen (PSMA)-based radioguided surgery (RGS) with short-term androgen deprivation therapy (ADT) improves oncological outcomes in men with oligorecurrent prostate cancer (PCa) as compared to treatment with short-term ADT only. METHODS: The TRACE-II study is an investigator-initiated, prospective, randomised controlled clinical trial. Patients (aged >18 years) with hormone-sensitive recurrent PCa after radical prostatectomy or radiotherapy (brachytherapy or external beam radiotherapy), with involvement of ≤2 lymph nodes or local oligorecurrent disease within the pelvis as determined by PSMA positron emission tomography (PET)/computed tomography (CT) are randomly assigned in a 1:1 ratio between 6-month ADT (Arm A) or 6-month ADT plus RGS (Arm B). The primary objective is to determine clinical progression-free survival (CPFS) at 24 months. After PSMA-RGS, CPFS is defined as the time between the start of treatment and the appearance of a re-recurrence (any N1 or M1) as suggested by PSMA-PET/CT or symptoms related to progressive PCa, or death from any cause. The secondary objectives include metastasis-free survival at 2, 5 and 10 years, biochemical progression-free survival at 2 years, and patient-reported quality of life at 2, 5 and 10 years. A total of 60 patients, 30 per arm, will be included. The trial is powered (80%) to detect at least a 30% absolute difference in CPFS between the two study arms in the period 2 years after randomisation. We expect to enrol the required participants in 3 years. The study has an expected duration of 5 years in total. CONCLUSIONS: Combining RGS with short-term ADT might be oncologically beneficial for patients with oligorecurrent PCa. In this first randomised controlled trial, we are investigating the potential oncological benefits of this combined treatment, while also focusing on maintaining quality of life.
引用
- Zuur LG, de Barros HA, van Oosterom MN, et al. 99mTcPSMA-radioguided surgery in oligorecurrent prostate cancer: the randomised TRACE-II trial. BJU Int. 2024. PMID: 38346924. doi:10.1111/bju.16297
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。